Patient-Reported Outcome Measures in the Food and Drug Administration Pilot Compendium: Meeting Today’s Standards for Patient Engagement in Development?

Food and Drug Administration. Clinical Outcome Assessment Qualification Program submissions. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm450689.htm. [Accessed June 1, 2017]. Food and Drug Administration. Roadmap to patient-focused outcome measurement in clinical trials. Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/UCM370174.pdf. [Accessed June 1, 2017]. 2009, Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Food and Drug Administration. Pilot Clinical Outcome Assessment Compendium (COA Compendium) Version 1. Available from: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM481225.pdf. [Accessed June 29, 2016]. Food and Drug Administration. Enhancing the development and use of patient-reported outcomes in drug development: July 16, 2014 meeting summary. Available from: https://www.brookings.edu/wp-content/uploads/2014/07/PRO-Expert-workshop-1_Meeting-Summary.pdf. [Accessed June 1, 2017]. Perfetto, 2015, Patient-focused drug development: a new direction for collaboration, Med Care, 53, 9, 10.1097/MLR.0000000000000273 Food and Drug Administration. Pilot Clinical Outcome Assessment Compendium (COA Compendium) Webinar (March 8, 2016). Available from: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/UCM489439.pdf. [Accessed June 25, 2016]. Miles, 1994 Benjamin, 2017, Patient-reported outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR COA Emerging Good Practices Task Force Report, Value Health, 20, 838, 10.1016/j.jval.2017.05.015 Patrick, 2011, Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 1—eliciting concepts for a new PRO instrument, Value Health, 14, 967, 10.1016/j.jval.2011.06.014 Patrick, 2011, Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2—assessing respondent understanding, Value Health, 14, 978, 10.1016/j.jval.2011.06.013 Rothman, 2009, Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force report, Value Health, 12, 1075, 10.1111/j.1524-4733.2009.00603.x 2006, Patient-reported outcome measures: use in medical product development to support labeling claims, Draft guidance. Psotka, 2016, Patient-reported outcomes in chronic heart failure: applicability for regulatory approval, JACC Heart Fail, 4, 791, 10.1016/j.jchf.2016.04.010 Green, 2000, Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure, J Am Coll Cardiol, 35, 1245, 10.1016/S0735-1097(00)00531-3 International Society for Quality of Life Research. ISOQOL commentary on FDA Compendium. Available from: http://www.isoqol.org/UserFiles/file/ISOQOLFDACompendiumCommentaryFinalDraft.pdf. [Accessed July 19, 2017]. Kleinman, 2014, Cdad-Daysymsâ: a new patient-reported outcome tool for Clostridium difficile-associated diarrhea, Value Health, 17, A569, 10.1016/j.jval.2014.08.1897 Frost, 2007, What is sufficient evidence for the reliability and validity of patient-reported outcome measures?, Value Health, 10, S94, 10.1111/j.1524-4733.2007.00272.x Doward, 2010, Patient-reported outcomes: looking beyond the label claim, Health Qual Life Outcomes, 8, 89, 10.1186/1477-7525-8-89 Newman, 2011, Copyright and open access at the bedside, N Engl J Med, 365, 2447, 10.1056/NEJMp1110652 Canestaro, 2016, Systematic review: patient-reported outcome measures in coeliac disease for regulatory submissions, Aliment Pharmacol Ther, 44, 313, 10.1111/apt.13703 Letter to FDA: Re: Docket No. FDA-2015-N-5106: Clinical Outcome Assessment Compendium. Available from: https://www.bio.org/sites/default/files/2016-03-14%20BIO%20Comments%20on%20COA%20Compendium%20FINAL.pdf. [Accessed July 19, 2017]. Todd, 2015, Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2), J Vasc Surg Venous Lymphat Disord, 3, 258, 10.1016/j.jvsv.2015.03.003 2012, 24 Vasquez, 2008, Venous Clinical Severity Score and quality-of-life assessment tools: application to vein practice, Phlebology, 23, 259, 10.1258/phleb.2008.008018 Paty, 2016, The VVSymQ(R) instrument: use of a new patient-reported outcome measure for assessment of varicose vein symptoms, Phlebology, 31, 481, 10.1177/0268355515595193 Wright, 2016, Psychometric evaluation of a new patient-reported outcome (PRO) symptom diary for varicose veins: VVSymQ(R) Instrument, Patient, 9, 335, 10.1007/s40271-015-0159-3 Paty, 2017, Content validity for the VVSymQ(R) Instrument: a new patient-reported outcome measure for the assessment of varicose veins symptoms, Patient, 10, 51, 10.1007/s40271-016-0183-y Abelson, 1990, Conjunctival allergen challenge: a clinical approach to studying allergic conjunctivitis, Arch Ophthalmol, 108, 84, 10.1001/archopht.1990.01070030090035 Abelson, 2003, Conjunctival allergen challenge: models in the investigation of ocular allergy, Curr Allergy Asthma Rep, 3, 363, 10.1007/s11882-003-0100-z DeMuro, 2012, Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006–2010, Value Health, 5, 443, 10.1016/j.jval.2012.01.010 Rahman, 2007, Pooled analysis of two clinical trials comparing the clinical outcomes of topical ciprofloxacin/dexamethasone otic suspension and polymyxin B/neomycin/hydrocortisone otic suspension for the treatment of acute otitis externa in adults and children, Clin Ther, 29, 1950, 10.1016/j.clinthera.2007.09.005 Monk, 1994, The Pittsburgh Sleep Diary, J Sleep Res, 3, 111, 10.1111/j.1365-2869.1994.tb00114.x Dupont, 2007, Treatment of travelers’ diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone, Clin Gastroenterol Hepatol, 5, 451, 10.1016/j.cgh.2007.02.004